A Phase II Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety, Tolerability and Efficacy of RG2417 (Uridine) in the Treatment of Bipolar I Depression.

Trial Profile

A Phase II Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety, Tolerability and Efficacy of RG2417 (Uridine) in the Treatment of Bipolar I Depression.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2011

At a glance

  • Drugs Uridine (Primary)
  • Indications Bipolar I disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Mar 2011 Top-line results from this study published in a Repligen Corporation media release.
    • 08 Mar 2011 Secondary endpoint 'Clinical-Global-Impressions-scale' has not been met
    • 08 Mar 2011 Primary endpoint 'Montgomery-Asberg-Depression-Rating-Scale' has not been met
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top